Related references
Note: Only part of the references are listed.Angiopoietin: A TIE(d) balance in tumor angiogenesis
Winston S. N. Shim et al.
MOLECULAR CANCER RESEARCH (2007)
Metronomic chemotherapy:: an antiangiogenic scheduling
B. Laquente et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts
Lova Segerstrom et al.
PEDIATRIC RESEARCH (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Regulation of angiogenesis by hypoxia: role of the HIF system
CW Pugh et al.
NATURE MEDICINE (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Metronomic scheduling: the future of chemotherapy?
G Gasparini
LANCET ONCOLOGY (2001)
Discovery of a novel Raf kinase inhibitor
JF Lyons et al.
ENDOCRINE-RELATED CANCER (2001)
Share Paper
